Filtered By:
Drug: Metformin
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 6422 results found since Jan 2013.
Case Report: Late-Onset Metformin-Associated Diarrhea
Am Fam Physician. 2023 Aug;108(2):Online.NO ABSTRACTPMID:37590844
Source: American Family Physician - August 17, 2023 Category: Primary Care Authors: Robert J Flaherty Source Type: research
Metformin and exercise effects on postprandial insulin sensitivity and glucose kinetics in pre-and-diabetic adults
Am J Physiol Endocrinol Metab. 2023 Aug 16. doi: 10.1152/ajpendo.00118.2023. Online ahead of print.ABSTRACTThe potential interaction between metformin and exercise on glucose-lowering effects remains controversial. We studied the separated and combined effects of metformin and/or exercise on fasting and postprandial insulin sensitivity in individuals with pre- and - type 2 diabetes (T2D). Eight T2D adults (60±4 years) with overweight/obesity (32±4 kg·m-2) under chronic metformin treatment (9±6 years; 1281±524 mg·day-1) underwent four trials; a) taking their habitual metformin treatment (MET), b) substituting during 9...
Source: American Journal of Physiology. Endocrinology and Metabolism - August 16, 2023 Category: Physiology Authors: Alfonso Moreno-Caba ñas Felix Morales-Palomo Laura Álvarez-Jimenez Diego Mora-Gonzalez Juan Fernando Ortega Ricardo Mora-Rodriguez Source Type: research
Efficacy of metformin in prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial
Conclusion: The use of metformin in breast cancer patients offered a marked protection against paclitaxel-induced PN, which translated to better patient QoL. Clinical Trial Registration: https://classic.clinicaltrials.gov/ct2/show/NCT05351021, identifier NCT05351021.PMID:37583905 | PMC:PMC10424931 | DOI:10.3389/fphar.2023.1181312
Source: Cancer Control - August 16, 2023 Category: Cancer & Oncology Authors: Hala M Bakry Noha O Mansour Tawfik R ElKhodary Moetaza M Soliman Source Type: research
GAL3 Mediates Vascular Dysfunction in Obesity by Regulating NOX1
CONCLUSIONS: Deletion of GAL3 normalizes microvascular endothelial function in obese db/db mice, likely through an NOX1-mediated mechanism. Pathological levels of GAL3, and in turn NOX1, are amenable to improvements in metabolic status, presenting a potential therapeutic target to ameliorate pathological cardiovascular consequences of obesity.PMID:37586054 | DOI:10.1161/ATVBAHA.123.319476
Source: Arteriosclerosis, Thrombosis and Vascular Biology - August 16, 2023 Category: Cardiology Authors: Caleb A Padgett R óbert K Bátori Andrew C Speese Cody L Rosewater Weston B Bush Cassandra C Derella Stephen B Haigh Hunter G Sellers Zachary L Corley Madison A West James D Mintz Brittany B Ange Ryan A Harris Michael W Brands David J R Fulton David W St Source Type: research
Approach to the Patient with Youth-Onset Type 2 Diabetes
J Clin Endocrinol Metab. 2023 Aug 16:dgad482. doi: 10.1210/clinem/dgad482. Online ahead of print.ABSTRACTYouth-onset type 2 diabetes is a growing epidemic with a rising incidence worldwide. Although the pathogenesis and diagnosis of youth-onset type 2 diabetes are similar to adult-onset type 2 diabetes, youth-onset type 2 diabetes is unique, with greater insulin resistance, insulin hypersecretion, and faster progression of pancreatic beta cell function decline. Individuals with youth-onset type 2 diabetes also develop complications at higher rates within short periods of time compared to adults with type 2 diabetes or yout...
Source: The Journal of Clinical Endocrinology and Metabolism - August 16, 2023 Category: Endocrinology Authors: Talia A Hitt Tamara S Hannon Sheela N Magge Source Type: research
